Drug Trial Radar · NCT06118905
Preserving Geriatric Muscle With an Osteoporosis Medication
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
155
Planned (sponsor's estimate)
Start
Feb 8, 2024
Primary completion
Feb 28, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Chrissy KistlerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
Conditions
- Osteoporosis
Interventions
Denosumab 60 MG/MLDrug
Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV
Zoledronic Acid 5Mg/Bag 100Ml InfusionDrug
Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Knee extension strength changeTime frame: 12 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Barnabas Woodlands
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.